LogicBio Therapeutics, Inc. engages in the development of a genome editing technology platform. The company is headquartered in Lexington, Massachusetts and currently employs 62 full-time employees. The company went IPO on 2018-10-19. The company is focused on genome editing and gene delivery platforms to address rare and serious diseases from infancy through adulthood. Its genome editing platform, GeneRide, is an approach to precise gene insertion harnessing a cell's natural deoxyribonucleic acid repair process, potentially to durable therapeutic protein expression levels. Its gene delivery platform, sAAVy, is an adeno-associated virus (AAV) capsid engineering platform designed to optimize gene delivery for treatments in a range of indications and tissues. Its lead product candidate, LB-001 is developed for the treatment of methylmalonic acidemia (MMA) in pediatric patients. LB-001 is designed to introduce a functional copy of the methylmalonyl-CoA mutase (MUT) gene into the genome of MMA patients. The company is developing LB-401 for the treatment of hereditary tyrosinemia type 1. The company is also developing LB-301 for the treatment of Crigler-Najjar syndrome (CN).

Industry: Biological Products, (No Diagnostic Substances) Peers: TELIX QSAM INC. Windtree Therapeutics Inc BELLICUM PHARMACEUTICALS, INC /entities/rdgad BioRestorative Therapies Inc Decoy Therapeutics Inc Canton Strategic Holdings Inc Lixte Biotechnology Holdings Inc ProtoKinetix Inc